(Total Views: 230)
Posted On: 01/13/2017 12:26:29 PM
Post# of 72433
![Avatar](https://investorshangout.com/images/ProfileImages/424989898_3046_Avatar jpeg2.jpg)
Article, big buy-outs in biotech. We knew about the huge price ARIA is fetching, but I didn't know that the Dendreon division of Valeant was sold for 819 million bucks. They have exactly one product, the prostate cancer incredibly expensive course of treatment with personalized immunotherapy.
http://www.fiercepharma.com/pharma-asia/fierc...oifQ%3D%3D
So if that non-standard treatment is worth 819 million, what would be the value of a treatment by a first-line drug for a more common disease, like psoriasis?
(rhetorical question)
http://www.fiercepharma.com/pharma-asia/fierc...oifQ%3D%3D
So if that non-standard treatment is worth 819 million, what would be the value of a treatment by a first-line drug for a more common disease, like psoriasis?
(rhetorical question)
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)